Text Size

The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Université de Montréal
ClinicalTrials.gov Identifier:
NCT00295412
First received: February 21, 2006
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the pharmacological treatment of this dual diagnosis population. Preliminary results suggest that second-generation antipsychotic drugs (mainly clozapine) may relieve drug cravings in schizophrenia. We performed a 12-week pilot study to evaluate the impact of quetiapine, a second-generation antipsychotic, on substance abuse parameters, psychiatric symptoms and side effects in patients schizophrenia and comorbid substance use disorders. Our expectation was a 20 % decrease in drug cravings from baseline to end-point.


Condition Intervention Phase
Schizophrenia
Substance Use Disorders
 Drug: quetiapine (drug)
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Université de Montréal:

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients with as schizophrenia spectrum disorder
  • Patients with a comorbid substance use disorder

Exclusion Criteria:

  • Patients already on quetiapine or clozapine
  • Patients hospitalized or acutely ill
  • Total score lower than 65 on the PANSS
  • Pregnancy
  • Female subjects of childbearing potential without adequate contraception
  • Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
  • Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00295412

Locations
Canada, Quebec
Centre de recherche Fernand-Seguin
Montreal, Quebec, Canada, H1N 3V2
Sponsors and Collaborators
Université de Montréal
AstraZeneca
Investigators
Principal Investigator: Emmanuel Stip, Md, MSc, CSPQ Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Departement of Psychiatry, Faculty of medicine, University of Montreal
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00295412     History of Changes
Other Study ID Numbers: 5077-99904
Study First Received: February 21, 2006
Last Updated: February 21, 2006
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Substance-Related Disorders
Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
 Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 23, 2013